<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?npg-journal-abbreviation?><?properties open_access?><?DTDIdentifier.IdentifierValue -//NPGSJ//DTD full length article DTD version 7.0 XML//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ajarticle_v7_x.dtd?><?SourceDTD.Version 7.0?><?ConverterInfo.XSLTName naturesa2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-title-group><journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title></journal-title-group><issn pub-type="epub">2163-8306</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4474171</article-id><article-id pub-id-type="pii">psp201439</article-id><article-id pub-id-type="doi">10.1038/psp.2014.39</article-id><article-id pub-id-type="pmid">25317724</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational
Modeling</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Monast</surname><given-names>C S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lazzara</surname><given-names>M J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Chemical and Biomolecular Engineering,
University of Pennsylvania</institution>, Philadelphia, Pennsylvania,
<country>USA</country></aff><aff id="aff2"><label>2</label><institution>Department of Bioengineering, University of
Pennsylvania</institution>, Philadelphia, Pennsylvania, <country>USA</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>(<email>mlazzara@seas.upenn.edu</email>)</corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>15</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2014</year></pub-date><volume>3</volume><issue>10</issue><fpage>e141</fpage><lpage/><history><date date-type="received"><day>28</day><month>05</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>07</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#169; 2014 American Society for Clinical Pharmacology and Therapeutics</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American Society for Clinical Pharmacology and Therapeutics</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0
Unported License. The images or other third party material in this article are included in the
article's Creative Commons license, unless indicated otherwise in the credit line; if the
material is not included under the Creative Commons license, users will need to obtain permission
from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link></license-p></license></permissions><abstract><p>We modeled cellular epidermal growth factor receptor (EGFR) tyrosine phosphorylation dynamics in
the presence of receptor-targeting kinase inhibitors (e.g., gefitinib) or antibodies (e.g.,
cetuximab) to identify systematically the factors that contribute most to the ability of the
therapeutics to antagonize EGFR phosphorylation, an effect we define here as biochemical efficacy.
Our model identifies distinct processes as controlling gefitinib or cetuximab biochemical efficacy,
suggests biochemical efficacy is favored in the presence of certain EGFR ligands, and suggests new
drug design principles. For example, the model predicts that gefitinib biochemical efficacy is
preferentially sensitive to perturbations in the activity of tyrosine phosphatases regulating EGFR,
but that cetuximab biochemical efficacy is preferentially sensitive to perturbations in ligand
binding. Our results highlight numerous other considerations that determine biochemical efficacy
beyond those reflected by equilibrium affinities. By integrating these considerations, our model
also predicts minimum therapeutic combination concentrations to maximally reduce receptor
phosphorylation.</p></abstract></article-meta></front><body><p>For various malignancies, small-molecule inhibitors and antibodies that antagonize the function
of oncogenic receptor tyrosine kinases are in use or in clinical trials. For the epidermal growth
factor receptor (EGFR), ATP analog kinase inhibitors including gefitinib and erlotinib are approved
for non&#8211;small cell lung carcinoma and pancreatic cancer,<sup><xref ref-type="bibr" rid="bib1">1</xref>,<xref ref-type="bibr" rid="bib2">2</xref></sup> and the ligand-competitive monoclonal antibody
cetuximab is approved for head and neck and colorectal cancers.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> While these therapeutics target the same receptor, there may be important
determinants of their abilities to antagonize EGFR-initiated signaling beyond the competitive
binding processes in which they participate, and those determinants may be unique for different
therapeutic classes owing to the different steps of the receptor phosphorylation process at which
the therapeutics act. Identifying such determinants may aid in the rational design of
next-generation therapeutics targeting EGFR and could provide insight into the differential
effectiveness of these therapeutics <italic>in vitro</italic> and <italic>in vivo</italic> (e.g., refs. <xref ref-type="bibr" rid="bib4">4</xref>,<xref ref-type="bibr" rid="bib5">5</xref>,<xref ref-type="bibr" rid="bib6">6</xref>).</p><p>Computational modeling represents a useful approach for systematically identifying processes that
determine the abilities of therapeutics to antagonize EGFR signal-initiating capacity. Of course, a
number of detailed kinetic models of EGFR signaling have been developed with varying levels of
complexity (e.g., refs. <xref ref-type="bibr" rid="bib7">7</xref>,<xref ref-type="bibr" rid="bib8">8</xref>,<xref ref-type="bibr" rid="bib9">9</xref>,<xref ref-type="bibr" rid="bib10">10</xref>,<xref ref-type="bibr" rid="bib11">11</xref>).
Surprisingly, none of these has been utilized to explore directly the determinants of the ability of
different classes of EGFR-targeted therapeutics to interrupt EGFR-initiated signaling. For EGFR and
other receptor tyrosine kinases, the well-known model of Cheng and Prusoff<sup><xref ref-type="bibr" rid="bib12">12</xref></sup> has also been invoked to make inferences about therapeutic efficacy (e.g., ref.
<xref ref-type="bibr" rid="bib13">13</xref>), but the simplicity of this model prevents a full analysis of all
receptor-level processes that may influence therapeutic effects (e.g., receptor trafficking).</p><p>Here, we build upon a previous model of EGFR phosphorylation dynamics to identify systematically
the key receptor-level processes that enable gefitinib and cetuximab to antagonize EGFR
phosphorylation in the cellular context. We focus on determinants of EGFR phosphorylation since that
is the initial step enabling EGFR to generate downstream signaling. We find that the processes that
determine biochemical efficacy (defined here as ability to reduce EGFR tyrosine phosphorylation)
extend beyond those involved in equilibrium EGFR-therapeutic binding and differ by therapeutic and
ligand. For example, gefitinib and cetuximab are predicted to be more effective when EGFR activation
is driven by amphiregulin (AR) than by epidermal growth factor (EGF) due to differences in affinity
and time scales for receptor occupancy. EGFR tyrosine dephosphorylation rate is predicted to be a
preferentially important determinant of gefitinib biochemical efficacy, while ligand binding rate is
a preferentially important determinant of cetuximab biochemical efficacy, again due to differences
in relevant process time scales. Our model also predicts how gefitinib and cetuximab can be most
efficiently combined to reduce receptor phosphorylation maximally but minimize drug concentrations
and redundant effects.</p><sec sec-type="results"><title>Results</title><sec><title>Inhibition of receptor phosphorylation by gefitinib or cetuximab</title><p>The model considers the rate processes leading to EGFR phosphorylation in cell surface and
interior compartments (<bold><xref ref-type="fig" rid="fig1">Figure 1a</xref></bold>). See <bold><xref rid="tbl1" ref-type="table">Table 1</xref></bold> for definitions and values of rate parameters. Reversibility of all processes
is considered, allowing gefitinib and cetuximab to antagonize EGFR phosphorylation not only for
already drug-bound receptors but through other rate processes, such as prolonging the
dephosphorylated receptor state after receptors are acted upon by protein tyrosine phosphatases
(<bold><xref ref-type="fig" rid="fig1">Figure 1b</xref></bold>). Throughout these results, we report therapeutic
biochemical efficacy in terms of an <italic>IC</italic><sub>50</sub>, defined as the therapeutic
concentration required to reduce steady EGFR phosphorylation to half its value in the absence of
therapeutic.</p><p>We begin by simulating inhibition curves for 10&#8201;ng/ml (1.6 nmol/l) EGF or equimolar AR for
all ligand/therapeutic combinations (<bold><xref ref-type="fig" rid="fig2">Figure 2a</xref></bold>). For cetuximab
and gefitinib, the predicted <italic>IC</italic><sub>50</sub> in the presence of EGF exceeds that for AR by
roughly an order of magnitude (<bold><xref ref-type="fig" rid="fig2">Figure 2b</xref></bold>). This occurs, in part,
because AR's lower affinity reduces receptor occupancy and the dimerization driving force. For
either ligand, the predicted <italic>IC</italic><sub>50</sub> is larger for gefitinib than cetuximab. This
occurs, in part, because the particular combinations of species concentrations and binding kinetics
disfavor gefitinib's competition with ATP more than cetuximab's with ligand. Additional
factors contribute to these differences, as will be discussed. To account for different ligand
affinities, we repeated the analysis for a 100-fold increase in AR concentration (<bold><xref ref-type="fig" rid="fig2">Figure 2c</xref></bold>). This reduces, but does not eliminate, predicted
<italic>IC</italic><sub>50</sub> differences (<bold><xref ref-type="fig" rid="fig2">Figure 2d</xref></bold>).</p></sec><sec><title>Effect of ligand and therapeutic binding kinetics on predicted <italic>IC</italic><sub>50</sub>
values for gefitinib and cetuximab</title><p>Given that differences in ligand affinity do not fully explain predicted <italic>IC</italic><sub>50</sub>
differences, we performed an analysis assuming constant affinities of ligand (based on EGF) and drug
(gefitinib or cetuximab) but varying rate constants for ligand and drug binding and unbinding by an
equal &#8220;cycling factor&#8221; (<bold><xref ref-type="fig" rid="fig3">Figure 3a</xref></bold>,<bold><xref ref-type="fig" rid="fig3">b</xref></bold>). Faster ligand cycling on and off the receptor generally reduces
predicted gefitinib and cetuximab <italic>IC</italic><sub>50</sub>. For example, a 10-fold increase in EGF
cycling from base values reduces gefitinib or cetuximab <italic>IC</italic><sub>50</sub> by ~25 or 40%,
respectively. This occurs because of a reduced phosphorylation driving force as the time scale for
ligand occupancy becomes similar or small compared to the time scale for ligand-bound receptors to
become phosphorylated, as reflected by decreased EGFR phosphorylation in the absence of drugs with
increasing ligand cycling (vertical grey scale bars in <bold><xref ref-type="fig" rid="fig3">Figure
3</xref></bold>).</p><p><bold><xref ref-type="fig" rid="fig3">Figure 3a</xref></bold>,<bold><xref ref-type="fig" rid="fig3">b</xref></bold> also show
predicted effects of changing gefitinib or cetuximab cycling. Sufficient decreases in gefitinib
cycling reduce gefitinib <italic>IC</italic><sub>50</sub> (<bold><xref ref-type="fig" rid="fig3">Figure 3a</xref></bold>),
consistent with the notion that irreversible EGFR kinase inhibitors are more effective than
reversible inhibitors.<sup><xref ref-type="bibr" rid="bib14">14</xref></sup> This occurs because the receptor
is increasingly less likely to rephosphorylate as the time scale with which it remains
inhibitor-bound increases. Consistent with this, sensitivity to gefitinib cycling decreases as EGFR
cycling through phosphorylated and unphosphorylated states slows (<bold><xref ref-type="fig" rid="fig3">Figure
3c</xref></bold>). In contrast, cetuximab's biochemical efficacy is relatively insensitive to
changes in cetuximab cycling (<bold><xref ref-type="fig" rid="fig3">Figure 3b</xref></bold>) because of competing
effects. As cetuximab cycling increases, <italic>IC</italic><sub>50</sub> tends to decrease because
cetuximab binds the receptor more slowly than ligand for the base parameters. That effect is offset,
however, because the time scale for cetuximab dissociation from EGFR decreases and approaches that
for receptor dephosphorylation as cetuximab cycling increases, which increases
<italic>IC</italic><sub>50</sub>. The modest net effect of cetuximab cycling on <italic>IC</italic><sub>50</sub> can
be eliminated by reducing receptor dimerization and uncoupling rates (<bold><xref ref-type="fig" rid="fig3">Figure
3d</xref></bold>) because cetuximab binding and dissociation steps are no longer rate limiting in the
competitive processes described above that allow cetuximab cycling to influence
<italic>IC</italic><sub>50</sub>. Not surprisingly, <italic>IC</italic><sub>50</sub> values are also reduced by this
parameter alteration.</p></sec><sec><title><italic>IC</italic><sub>50</sub> sensitivity analysis</title><p>To identify other processes that determine <italic>IC</italic><sub>50</sub>, we performed parameter
sensitivity analyses. The predicted gefitinib <italic>IC</italic><sub>50</sub> in the presence of 1.6 nmol/l
EGF is most sensitive to perturbations in parameters for ATP binding
(<italic>k</italic><sub><italic>A,f</italic></sub> and <italic>k</italic><sub><italic>A,r</italic></sub>), gefitinib binding
(<italic>k</italic><sub><italic>g,f</italic></sub> and <italic>k</italic><sub><italic>g,r</italic></sub>), EGFR phosphorylation
(<italic>k</italic><sub><italic>p,L</italic></sub>), and EGFR dephosphorylation (<italic>k</italic><sub><italic>dp,s</italic></sub>
and <italic>k</italic><sub><italic>dp,i</italic></sub>) (<bold><xref ref-type="fig" rid="fig4">Figure 4a</xref></bold>). Sensitivity
to perturbations in ATP and gefitinib binding is anticipated because these parameters control
gefitinib/ATP competition. Sensitivity to changes in <italic>k</italic><sub><italic>dp,s</italic></sub>,
<italic>k</italic><sub><italic>dp,I</italic></sub>, and <italic>k</italic><sub><italic>p,L</italic></sub> arises because of the
importance of receptor dephosphorylation and phosphorylation cycles in setting steady
phosphorylation. The gefitinib <italic>IC</italic><sub>50</sub> in the presence of 1.6 nmol/l AR is
sensitive to perturbations in ATP and gefitinib binding but relatively insensitive to perturbations
in <italic>k</italic><sub><italic>p,L</italic></sub><italic>, k</italic><sub><italic>dp,s</italic></sub>, and
<italic>k</italic><sub><italic>dp,i</italic></sub> because 1.6 nmol/l AR does not promote substantial dimerization
or phosphorylation. For 160 nmol/l AR, the number of dimers present at steady-state increases
&gt;20-fold, and the model predicts increased sensitivity to perturbations in parameters for
ligand-receptor association and dissociation (<italic>k</italic><sub><italic>L,fs</italic></sub> and
<italic>k</italic><sub><italic>L,rs</italic></sub>, respectively), <italic>k</italic><sub><italic>p,L</italic></sub><italic>,
k</italic><sub><italic>dp,s</italic></sub>, and <italic>k</italic><sub><italic>dp,i</italic></sub>.</p><p>For cetuximab, the <italic>IC</italic><sub>50</sub> in the presence of 1.6 nmol/l EGF <inline-formula id="eque1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e1.jpg"/></inline-formula> is most sensitive to perturbations in
<italic>k</italic><sub><italic>L,fs</italic></sub> and <italic>k</italic><sub><italic>L,rs</italic></sub>, rate constants for
EGFR-cetuximab binding (<italic>k</italic><sub><italic>c,f</italic></sub> and <italic>k</italic><sub><italic>c,r</italic></sub>),
and rate constants for EGFR internalization and sorting (<italic>k</italic><sub><italic>i</italic></sub> and
<italic>k</italic><sub><italic>x</italic></sub>) (<bold><xref ref-type="fig" rid="fig4">Figure 4b</xref></bold>). Competition of
cetuximab with ligand for EGFR binding explains sensitivity to cetuximab and EGF binding parameters.
Sensitivity to <italic>k</italic><sub><italic>i</italic></sub> and <italic>k</italic><sub><italic>x</italic></sub> arises because
cetuximab binds EGFR at the cell surface, and these parameters control EGFR distribution between the
cell surface and interior. <inline-formula id="eque2"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e2.jpg"/></inline-formula> is
insensitive to perturbations in <italic>k</italic><sub><italic>p,L</italic></sub>,
<italic>k</italic><sub><italic>dp,s</italic></sub>, or <italic>k</italic><sub><italic>dp,i</italic></sub> because cetuximab
indirectly disrupts receptor phosphate cycling by preventing receptor monomers from dimerizing.
Relatively slow dephosphorylation is sufficient to reduce receptor phosphorylation in this context.
For 1.6 nmol/l AR <inline-formula id="eque3"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e3.jpg"/></inline-formula>, we observe
sensitivity mainly to the cetuximab binding parameters (<bold><xref ref-type="fig" rid="fig4">Figure
4b</xref></bold>), which arises because EGFR occupancy is so low that perturbations in AR binding
constants cannot promote substantial competition with cetuximab. <inline-formula id="eque4"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e4.jpg"/></inline-formula> is relatively insensitive to perturbations in
<italic>k</italic><sub><italic>i</italic></sub> and <italic>k</italic><sub><italic>x</italic></sub> because there is little EGFR
internalization for this AR concentration. Increasing AR concentration sensitizes <inline-formula id="eque5"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e5.jpg"/></inline-formula> to ligand binding and trafficking
parameters, as binding and endocytosis become more robust with the larger AR concentration
(<bold><xref ref-type="fig" rid="fig4">Figure 4b</xref></bold>).</p><p>Note that parameter sensitivity results are not shown in <bold><xref ref-type="fig" rid="fig4">Figure
4</xref></bold> for perturbations to EGFR, GRB2, or ATP concentrations because results for those
simulations reflect effects already shown through variations in the parameters that control process
steps in which those species are involved. For example, the relative importance of changing EGFR
expression is reflected by results for perturbations in receptor dimerization parameters.</p></sec><sec><title>Kinetics of therapeutic-mediated reductions in EGFR phosphorylation</title><p>Our results suggest that some differences in gefitinib and cetuximab <italic>IC</italic><sub>50</sub>
determinants arise because the kinetics with which phosphorylated receptors become dephosphorylated
(and eventually rephosphorylated) in the presence of drugs influence <italic>IC</italic><sub>50</sub>. This
dependence arises because of the small time scales for the many reversible processes considered
relative to receptor lifetime, and such effects can be observed in calculations of EGFR
phosphorylation response to therapeutics. For example, the relative insensitivity of cetuximab
<italic>IC</italic><sub>50</sub> to dephosphorylation kinetics can be elucidated by considering predicted
receptor dephosphorylation kinetics in response to cetuximab versus gefitinib after an initial
ligand pulse (<bold><xref ref-type="fig" rid="fig5">Figure 5a</xref></bold>). Gefitinib reduces EGFR phosphorylation
more rapidly than an equimolar dose of cetuximab, as indicated by time scales for phosphorylated
EGFR reductions (<italic>t</italic><sub>50</sub>) of 0.2 and 7.7&#8201;min, respectively. These differences
arise because cetuximab competes with relatively slow dimer uncoupling and ligand dissociation
processes, while gefitinib competes with relatively rapid ATP dissociation. Thus, reducing EGFR
internalization, to ensure EGFR access to cetuximab, and increasing ligand cycling, which promotes
dimer uncoupling, produces nearly identical gefitinib and cetuximab <italic>t</italic><sub>50</sub> values
(<bold><xref ref-type="fig" rid="fig5">Figure 5b</xref></bold>). For 1.6 nmol/l or 160 nmol/l AR, the predicted
<italic>t</italic><sub>50</sub> values are similar for the therapeutics because AR cycles more rapidly than
EGF (<bold><xref ref-type="fig" rid="fig5">Figure 5c</xref></bold>,<bold><xref ref-type="fig" rid="fig5">d</xref></bold>).</p><p>To further identify processes that influence the time scales with which therapeutics reduce
receptor phosphorylation, we performed parameter sensitivity analyses for <italic>t</italic><sub>50</sub>
calculations (<bold><xref ref-type="fig" rid="fig5">Figure 5e</xref></bold>,<bold><xref ref-type="fig" rid="fig5">f</xref></bold>).
The <italic>t</italic><sub>50</sub> for 1.6 nmol/l EGF and 1 &#181;mol/l gefitinib <inline-formula id="eque6"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e6.jpg"/></inline-formula> is sensitive to perturbations in
<italic>k</italic><sub><italic>dp,s</italic></sub> and <italic>k</italic><sub><italic>dp,i</italic></sub>,
<italic>k</italic><sub><italic>p,L</italic></sub>, <italic>k</italic><sub><italic>A,f</italic></sub> and
<italic>k</italic><sub><italic>A,r</italic></sub>, <italic>k</italic><sub><italic>g,f</italic></sub> and
<italic>k</italic><sub><italic>g,r</italic></sub>, <italic>k</italic><sub><italic>i</italic></sub>, and parameters for GRB2-EGFR
binding (<italic>k</italic><sub><italic>G</italic>2<italic>,f</italic></sub> and
<italic>k</italic><sub><italic>G</italic>2<italic>,r</italic></sub>) (<bold><xref ref-type="fig" rid="fig5">Figure 5e</xref></bold>).
Sensitivity to <italic>k</italic><sub><italic>G</italic>2<italic>,f</italic></sub>,
<italic>k</italic><sub><italic>G</italic>2<italic>,r</italic></sub>, and <italic>k</italic><sub><italic>i</italic></sub> is observed because
GRB2 binding protects tyrosines from dephosphorylation and because the endosomal compartment is
characterized by different kinetics for processes leading to receptor phosphorylation and
dephosphorylation. The <italic>t</italic><sub>50</sub> for 1.6 nmol/l AR and 1 &#181;mol/l gefitinib
<inline-formula id="eque7"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e7.jpg"/></inline-formula> is most sensitive to perturbations
in <italic>k</italic><sub><italic>dp,s</italic></sub>, <italic>k</italic><sub><italic>dp,i</italic></sub> and
<italic>k</italic><sub><italic>G</italic>2<italic>,f</italic></sub> and <italic>k</italic><sub><italic>G</italic>2<italic>,r</italic></sub>.
<inline-formula id="eque8"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e8.jpg"/></inline-formula> is less sensitive to perturbations
in <italic>k</italic><sub><italic>p,L</italic></sub> than <inline-formula id="eque9"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e9.jpg"/></inline-formula> because of a reduced dimerization driving force in the presence of AR. For 160
nmol/l AR, <inline-formula id="eque10"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e10.jpg"/></inline-formula> sensitivity to
perturbations in <italic>k</italic><sub><italic>p,L</italic></sub> increases but is still lower than that for 1.6
nmol/l EGF due to rapid AR dissociation.</p><p>The <italic>t</italic><sub>50</sub> for 1.6 nmol/l EGF and 1 &#181;mol/l cetuximab <inline-formula id="eque11"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e11.jpg"/></inline-formula> is most sensitive to changes in
<italic>k</italic><sub><italic>L,fs</italic></sub>, <italic>k</italic><sub><italic>L,rs</italic></sub>,
<italic>k</italic><sub><italic>G2,f</italic></sub>, <italic>k</italic><sub><italic>G2,r</italic></sub>,
<italic>k</italic><sub><italic>dp,i</italic></sub>, <italic>k</italic><sub><italic>i</italic></sub>, and
<italic>k</italic><sub><italic>x</italic></sub> (<bold><xref ref-type="fig" rid="fig5">Figure 5f</xref></bold>). Compared to <inline-formula id="eque12"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e12.jpg"/></inline-formula>, <inline-formula id="eque13"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e13.jpg"/></inline-formula> is less sensitive to perturbations in dephosphorylation parameters
and more sensitive to perturbations in ligand binding parameters because ligand dissociation is more
rate-limiting for cetuximab-mediated reductions in EGFR phosphorylation than tyrosine
dephosphorylation. The <italic>t</italic><sub>50</sub> for 1.6 nmol/l AR and 1 &#181;mol/l cetuximab
<inline-formula id="eque14"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e14.jpg"/></inline-formula> is most sensitive to changes in
<italic>k</italic><sub><italic>c,f</italic></sub>, <italic>k</italic><sub><italic>G2,f</italic></sub>,
<italic>k</italic><sub><italic>G2,r</italic></sub>, <italic>k</italic><sub><italic>dp,s</italic></sub>, and
<italic>k</italic><sub><italic>dp,i</italic></sub>. Since AR-EGFR dissociation is more rapid than EGF-EGFR
dissociation, dephosphorylation is more rate-limiting for cetuximab-mediated reduction in EGFR
phosphorylation in the presence of 1.6 nmol/l AR than 1.6 nmol/l EGF. For 160 nmol/l AR, <inline-formula id="eque15"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e15.jpg"/></inline-formula> is sensitive to perturbations in ligand
binding parameters, <italic>k</italic><sub><italic>c,f</italic></sub>, GRB2 binding parameters, dephosphorylation
parameters, and <italic>k</italic><sub><italic>i</italic></sub>. Increasing the AR concentration tends to promote
receptor dimerization and phosphorylation, but does not promote receptor internalization as
efficiently as 1.6 nmol/l EGF. Thus, <inline-formula id="eque16"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439e16.jpg"/></inline-formula> remains sensitive to <italic>k</italic><sub><italic>dp,s</italic></sub> perturbations.</p><p>We repeated this analysis for 50 nmol/l gefitinib or cetuximab to explore differences that may
arise with drug concentrations at the lower end of those reported <italic>in vivo</italic><sup><xref ref-type="bibr" rid="bib15">15</xref></sup> (<bold>Supplementary</bold>
<bold>Figure S1a,b</bold>). Relative sensitivity to perturbations in parameters for binding of
therapeutics and binding processes with which therapeutic binding competes were increased at these
lower drug concentrations due to the fact that drugs are in greater competition for binding to
receptors when drug concentrations are reduced. Many of the other parameter sensitivities that were
observed for 1 &#181;mol/l drug concentrations were also observed here.</p></sec><sec><title>Predicted effects of gefitinib and cetuximab in combination</title><p>The clinical utility of combining cetuximab with erlotinib is the focus of ongoing clinical
trials (e.g., clinicaltrials.gov ID: NCT00397384). Because our analysis highlights how gefitinib and
cetuximab antagonize EGFR phosphorylation through different mechanisms, we used the model to predict
the effects of combining cetuximab and gefitinib. For a particular cetuximab or gefitinib
concentration, the model predicts that addition of the other therapeutic further decreases
steady-state EGFR phosphorylation in the presence of EGF or AR (<bold><xref ref-type="fig" rid="fig6">Figure
6a</xref></bold>&#8211;<bold><xref ref-type="fig" rid="fig6">c</xref></bold>). For our model structure, these effects
are not synergistic (<bold><xref ref-type="fig" rid="fig6">Figure 6d</xref></bold>&#8211;<bold><xref ref-type="fig" rid="fig6">f</xref></bold>). In fact, negative synergies are predicted for all combinations, resulting from
redundant effects that are most apparent at high drug concentrations. The most efficient
cotreatments would minimize receptor phosphorylation and redundant effects, while using the lowest
drug concentrations to avoid off-target toxicity. With this in mind, we estimated combination
efficiency by scaling pEGFR, synergy, and the logarithm of the total drug concentration between 0
and 1 and summing these values for each combination (<bold><xref ref-type="fig" rid="fig6">Figure
6g</xref></bold>&#8211;<bold><xref ref-type="fig" rid="fig6">i</xref></bold>). This calculation provides new
perspectives for how to combine cetuximab and gefitinib optimally. For example, consider the effects
of increasing gefitinib concentration for a fixed cetuximab concentration at 1.6 nmol/l EGF.
Starting from ~8 nmol/l cetuximab and 10<sup>&#8722;1</sup> nmol/l gefitinib and increasing
gefitinib, efficiency initially decreases until a ~20 nmol/l gefitinib because pEGFR levels are not
significantly affected until that point. Beyond ~20 nmol/l gefitinib, efficiency increases beyond
its starting point as pEGFR decreases. Efficiency eventually decreases again as drug effects become
increasingly redundant. Similar effects occur for AR, but with shifts in efficiency values over the
concentration space due to AR's differential ability to drive receptor phosphorylation.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Our finding that the abilities of cetuximab and gefitinib to antagonize EGFR phosphorylation are
determined by processes beyond those describing equilibrium drug binding motivates new consideration
of optimal design strategies for EGFR-targeted therapeutics. To the extent that EGFR phosphorylation
level correlates with clinical efficacy, these results also identify possible factors that could
underlie the differential effectiveness of the therapeutics among patients. Of course, a number of
limitations should be kept in mind in considering the implications of our results. Our analysis
implicitly assumes that decreased EGFR phosphorylation will produce more effective therapeutic
results. Of course, EGFR transduces signals through numerous pathways, and the integrated effects
ultimately determine phenotypic outcomes.<sup><xref ref-type="bibr" rid="bib16">16</xref></sup> Given that
receptor&#8211;adaptor association is required for downstream signaling, however, computing the
<italic>IC</italic><sub>50</sub> for EGFR-GRB2 complex formation may provide additional insight.
Interestingly, the relatively rapid kinetics of EGFR-GRB2 binding,<sup><xref ref-type="bibr" rid="bib17">17</xref></sup> which may not prevail for all EGFR adaptors, produces EGFR-GRB2 complex
sensitivity results that are indistinguishable from those for phosphorylated receptor
(<bold>Supplementary Figure S2a&#8211;d</bold>). Of course, our analysis also neglects the potential
importance of antibody-mediated cytotoxicity and kinase inhibitor off-target effects. These
limitations notwithstanding, a number of novel inferences can be drawn from our results.</p><p>Our identification of EGFR dephosphorylation kinetics as a key determinant of therapeutic
biochemical efficacy is intriguing given that the activities of protein tyrosine phosphatases that
regulate EGFR are altered in certain cancer settings.<sup><xref ref-type="bibr" rid="bib18">18</xref></sup>
For example, the receptor-like phosphatase protein tyrosine phosphatase receptor-type S (PTPRS) was
found deleted in ~25% of head and neck squamous cell carcinomas.<sup><xref ref-type="bibr" rid="bib19">19</xref></sup> PTPRS deletion was associated with elevated EGFR phosphorylation in tumor
tissues, and PTPRS knockdown augmented resistance to erlotinib in head and neck squamous cell
carcinomas cell lines. Interestingly, head and neck squamous cell carcinomas cell lines displaying
cetuximab resistance also displayed decreased PTPRS expression. Our model does predict some
cetuximab <italic>IC</italic><sub>50</sub> dependence on EGFR dephosphorylation kinetics, but it also
predicts that other factors are stronger determinants of cetuximab's ability to reduce EGFR
phosphorylation.</p><p>Our results also predict <italic>IC</italic><sub>50</sub> dependence on the rates of drug and ligand
association and dissociation, even for constant affinities. Our prediction that slowing
EGFR-gefitinib binding and dissociation cycling decreases <italic>IC</italic><sub>50</sub> is consistent
with the observation that slower erlotinib cycling promotes growth inhibition of lung and brain
cancer cells.<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> Importantly, Barkovich <italic>et
al</italic>.<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> noted that slower erlotinib cycling did not
correlate with reduced EGFR phosphorylation, possibly due to the relatively high concentrations of
erlotinib required for an effect on cell growth. Our prediction that ligand association and
dissociation kinetics affect <italic>IC</italic><sub>50</sub> suggests that different EGFR ligands, which
may bind EGFR with different kinetics,<sup><xref ref-type="bibr" rid="bib21">21</xref></sup> may result in
different therapeutic <italic>IC</italic><sub>50</sub> values. Relative mRNA levels of different EGFR
ligands generally vary among cells, as in gastric and colon cancer cell lines.<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> Thus, variable therapeutic responses among cells or tumors could be
partially related to differential ligand expression profiles.</p><p>While our model predicts cetuximab <italic>IC</italic><sub>50</sub> sensitivity to
<italic>k</italic><sub><italic>i</italic></sub> perturbations, only modest <italic>k</italic><sub><italic>i</italic></sub>
sensitivity is predicted for gefitinib (<bold><xref ref-type="fig" rid="fig4">Figure 4a</xref></bold>). This occurs
because cetuximab binds EGFR only at the cell surface, while gefitinib is available to EGFR in both
cellular compartments. This is interesting to consider in light of findings that increased EGFR
internalization, driven by <italic>ERK2</italic> amplification, can increase the <italic>IC</italic><sub>50</sub>
for WZ4002, an irreversible EGFR inhibitor, in PC9 cells.<sup><xref ref-type="bibr" rid="bib23">23</xref></sup> The basis for this effect remains unknown, but it could result from lower
protein tyrosine phosphatase activity against EGFR in the endosomal compartment versus the membrane
in PC9 cells. In that scenario, increasing receptor internalization would increase gefitinib
<italic>IC</italic><sub>50</sub>. Interestingly, cetuximab resistance correlates with increased EGFR
ubiquitination in colorectal cancer cells generated through prolonged cetuximab
exposure,<sup><xref ref-type="bibr" rid="bib24">24</xref></sup> which could also be related to EGFR
internalization effects.<sup><xref ref-type="bibr" rid="bib25">25</xref></sup> Other studies have linked
impaired EGFR internalization with cetuximab resistance.<sup><xref ref-type="bibr" rid="bib26">26</xref></sup>
Such inconsistencies may occur because endocytosis perturbations can arise for a variety of reasons,
with varied consequences for downstream signaling.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Model topology</title><p>A kinetic model of EGFR phosphorylation at a representative tyrosine was implemented using a
framework similar to one previously described,<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> but with
several alterations. The updated model includes kinetics for cetuximab binding to EGFR's
extracellular domain and for intracellular GRB2 binding to the phosphorylated receptor, and assumes
that GRB2-bound receptors internalize at experimentally measured rates for EGFR
endocytosis.<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> Note that data for EGFR Y1068 dynamics are
used for model training (described below), and that EGFR Y1068 is the primary GRB2 binding site in
the EGFR cytoplasmic tail.<sup><xref ref-type="bibr" rid="bib28">28</xref></sup> The model considers cell
surface and interior compartments (<bold><xref ref-type="fig" rid="fig1">Figure 1a</xref></bold>), with the interior
(endosomal) volume modeled as before.<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> In each
compartment, EGFR monomers reversibly bind ligands and ATP and homodimerize. Ligands and ATP also
reversibly bind receptor dimers. Dimerized, ATP-bound receptors undergo phosphorylation
characterized by rate constants <italic>k</italic><sub><italic>p</italic></sub> or
<italic>k</italic><sub><italic>p,L</italic></sub>, depending on receptor-ligand occupancy. In the surface
compartment, phosphorylated receptors are dephosphorylated or bind GRB2, which plays a general
adaptor role because of its signaling and endocytosis functions.<sup><xref ref-type="bibr" rid="bib29">29</xref>,<xref ref-type="bibr" rid="bib30">30</xref></sup> GRB2-bound receptors in the surface
compartment irreversibly move to the endosome.<sup><xref ref-type="bibr" rid="bib29">29</xref></sup>
Dephosphorylation at the cell surface and in the cell interior are characterized by parameters
<italic>k</italic><sub><italic>dp,s</italic></sub> and <italic>k</italic><sub><italic>dp,i</italic></sub>, respectively. Rules for
model reactions are further explained in <bold>Supplementary Materials</bold>. Model parameters are
provided in <bold><xref rid="tbl1" ref-type="table">Table 1</xref></bold>.</p></sec><sec><title>Asymmetric receptor dimers</title><p>In our previous model,<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> only symmetric receptor
dimerizations were permitted (e.g., a ligand-bound EGFR could only dimerize with another
ligand-bound EGFR) to limit model combinatorial complexity. In the updated model, we allowed for
asymmetric dimerization with respect to ligand occupancy to reflect an updated structural
understanding of dimers.<sup><xref ref-type="bibr" rid="bib31">31</xref></sup></p></sec><sec><title>EGFR-therapeutic binding</title><p>Gefitinib is assumed to compete with ATP regardless of EGFR localization. The model assumes that
cetuximab binds only surface-localized non-ligand-bound EGFR monomers.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> Cetuximab is modeled as a monovalent binder of EGFR to focus on a more
straightforward comparison between drugs that compete with single ligand or ATP binding events in
the extracellular or intracellular compartments, respectively, but the slightly enhanced binding
affinity observed for the bivalent full-length antibody<sup><xref ref-type="bibr" rid="bib32">32</xref></sup>
was used in model parameterization. Note that monovalent cetuximab fragments potently reduce EGFR
phosphorylation in cultured cells.<sup><xref ref-type="bibr" rid="bib32">32</xref></sup> Cetuximab-bound
species are permitted to internalize, but cetuximab dissociation is not permitted in the endosome by
considering numerical issues. Given that EGFR&#8211;cetuximab dissociation and endosomal exit rate
constants are of similar magnitude (<bold><xref rid="tbl1" ref-type="table">Table 1</xref></bold>), this assumption
should not significantly affect model predictions.</p><p>The model allows cetuximab and gefitinib to antagonize phosphorylation through processes beyond
the static sequestration of EGFR from entering the overall path leading to phosphorylation. For
example, cetuximab can bind to phosphorylated receptors generated through uncoupling of
phosphorylated dimers and dissociation of ligand (<bold><xref ref-type="fig" rid="fig1">Figure 1b</xref></bold>),
preventing receptors from re-dimerizing and -phosphorylating after dephosphorylation. Similarly,
gefitinib can bind phosphorylated receptors after ADP dissociation, antagonizing further rounds of
phosphorylation (<bold><xref ref-type="fig" rid="fig1">Figure 1b</xref></bold>).</p></sec><sec><title>EGFR ligands</title><p>EGF binding constants were based on experimental measurements.<sup><xref ref-type="bibr" rid="bib21">21</xref>,<xref ref-type="bibr" rid="bib33">33</xref></sup> AR was assumed to dissociate from EGFR 100
times faster than EGF, based on studies suggesting that AR has a larger dissociation constant
(<italic>K</italic><sub><italic>D</italic></sub>),<sup><xref ref-type="bibr" rid="bib34">34</xref></sup> is 50&#8211;300 times
less potent in cell growth assays,<sup><xref ref-type="bibr" rid="bib35">35</xref></sup> and less efficiently
promotes EGFR phosphorylation, CBL association, and ubiquitination.<sup><xref ref-type="bibr" rid="bib36">36</xref></sup> Ligand binding affinities were assumed in the endosome due to the known effects
of reduced pH in that compartment.<sup><xref ref-type="bibr" rid="bib21">21</xref></sup> With the differences
in ligand binding kinetics for EGF and AR, our model recapitulates published experimental findings
that AR is much less efficient than EGF in promoting EGFR endocytosis,<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> with model-predicted specific rate constants for receptor endocytosis of 0.01 or
0.13&#8201;min<sup>&#8722;1</sup> for 1.6 nmol/l AR or EGF, respectively.</p></sec><sec><title>Comparing therapeutics</title><p>For fixed concentration comparisons, we assumed 1 &#956;mol/l or 50 nmol/l for gefitinib and
cetuximab. 1 &#956;mol/l significantly exceeds the binding constant of either therapeutic with EGFR
(2.1 nmol/l for gefitinib and 5.2 nmol/l for cetuximab)<sup><xref ref-type="bibr" rid="bib1">1</xref>,<xref ref-type="bibr" rid="bib38">38</xref></sup> and is consistent with some reports of achievable therapeutic
concentrations <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="bib39">39</xref>,<xref ref-type="bibr" rid="bib40">40</xref></sup> 50 nmol/l concentrations were used in some calculations to span the range of
concentrations reported <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="bib15">15</xref></sup></p></sec><sec><title>Inhibition curves and <italic>IC</italic><sub>50</sub> calculations</title><p>We defined <italic>IC</italic><sub>50</sub> as the therapeutic concentration at which steady EGFR
phosphorylation was reduced to half its value in the absence of therapeutic, a definition used in
other studies (e.g., ref. <xref ref-type="bibr" rid="bib41">41</xref>). Inhibition curves were simulated by
computing steady EGFR phosphorylation in the presence of ligand over a range of therapeutic
concentrations. In making these calculations, we lumped all phosphorylated receptors regardless of
binding partners or localization. EGFR degradation and synthesis were not considered due to the
computationally intensive algorithm needed to determine the synthesis rate with the specific model
structure implemented here.<sup><xref ref-type="bibr" rid="bib27">27</xref></sup></p></sec><sec><title>Pulse-chase curves and <italic>t</italic><sub>50</sub> calculation</title><p>To quantify the rate with which therapeutics reduce EGFR phosphorylation, we simulated
5&#8201;min treatments of cells with ligands followed by 1 &#956;mol/l or 50 nmol/l therapeutic
chases. <italic>t</italic><sub>50</sub> is defined as the time required for 50% of the maximum possible
reduction in EGFR phosphorylation. For these calculations, EGFR degradation was not permitted in
order to reach a steady state.</p></sec><sec><title>Sensitivity analysis</title><p>To quantify the relative importance of receptor-level processes in determining
<italic>IC</italic><sub>50</sub> and <italic>t</italic><sub>50</sub>, we computed sensitivities to model parameter
perturbations. Sensitivity was defined as the absolute value of the difference in the logarithm of
<italic>IC</italic><sub>50</sub> or <italic>t</italic><sub><italic>50</italic></sub> values between the perturbed and base
parameter values, summed over all perturbations with parameters perturbed by 10- or 0.1-fold.</p></sec><sec><title>Model training</title><p>To capture realistic EGFR dephosphorylation kinetics, we fit <italic>k</italic><sub><italic>dp,s</italic></sub>
and <italic>k</italic><sub><italic>dp,i</italic></sub> using our published data for EGFR Y1068 phosphorylation
response to EGF, pervanadate, and gefitinib (<bold>Supplementary</bold><bold> Figure S3a&#8211;c</bold>), as
previously described.<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> Twenty fits were run, with small
variations among results. The <italic>k</italic><sub><italic>dp,s</italic></sub> and
<italic>k</italic><sub><italic>dp,i</italic></sub> values producing the lowest residual were chosen (<bold><xref rid="tbl1" ref-type="table">Table 1</xref></bold>). These values were slightly increased compared to those in our
previous study,<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> due to the updated model's
consideration of GRB2 binding to EGFR, which protects EGFR phosphotyrosines from
dephosphorylation.</p></sec><sec><title>Representative cell</title><p>Cells were assumed to express 5.0&#8201;&#215;&#8201;10<sup>4</sup> EGFR<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> and 2.1&#8201;&#215;&#8201;10<sup>5</sup> GRB2.<sup><xref ref-type="bibr" rid="bib43">43</xref></sup> ATP concentration was assumed to be 1 mmol/l.<sup><xref ref-type="bibr" rid="bib44">44</xref></sup> EGFR internalization was assumed to be consistent with a specific
endocytosis rate constant of 0.13&#8201;min<sup>&#8722;1</sup>,<sup><xref ref-type="bibr" rid="bib45">45</xref></sup> using an algorithm described previously.<sup><xref ref-type="bibr" rid="bib27">27</xref></sup></p></sec></sec><sec><title>Author Contributions.</title><p>C.S.M. and M.J.L. designed the research, analyzed the data, and wrote the manuscript. C.S.M.
performed the research.</p></sec><sec><title>Conflicts of Interest.</title><p>The authors declared no conflicts of interest.</p></sec><sec><title>Study Highlights</title><p>
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439i1.jpg"/>


</p></sec></body><back><ack><p>This work was supported in part by grant IRG-78-002-30 from the American Cancer Society and by
funding to M.J.L. from the University of Pennsylvania. We also thank Janine Buonato for review of
the manuscript.</p></ack><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakeling</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with
potential for cancer therapy</article-title><source>Cancer Res</source><volume>62</volume><fpage>5749</fpage><lpage>5754</lpage><year>2002</year><pub-id pub-id-type="pmid">12384534</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>V.A.</given-names></name><etal/></person-group><article-title>Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human
carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic
mice</article-title><source>J. Pharmacol. Exp. Ther</source><volume>291</volume><fpage>739</fpage><lpage>748</lpage><year>1999</year><pub-id pub-id-type="pmid">10525095</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Schmitz</surname><given-names>K.R.</given-names></name><name><surname>Jeffrey</surname><given-names>P.D.</given-names></name><name><surname>Wiltzius</surname><given-names>J.J.</given-names></name><name><surname>Kussie</surname><given-names>P.</given-names></name><name><surname>Ferguson</surname><given-names>K.M.</given-names></name></person-group><article-title>Structural basis for inhibition of the epidermal growth factor receptor by
cetuximab</article-title><source>Cancer Cell</source><volume>7</volume><fpage>301</fpage><lpage>311</lpage><year>2005</year><pub-id pub-id-type="pmid">15837620</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung
cancer</article-title><source>Cancer Chemother. Pharmacol</source><volume>69</volume><fpage>1241</fpage><lpage>1246</lpage><year>2012</year><pub-id pub-id-type="pmid">22278730</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Fan</surname><given-names>Z.</given-names></name></person-group><article-title>Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth
factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible
factor-1alpha</article-title><source>Mol. Cancer</source><volume>6</volume><fpage>63</fpage><year>2007</year><pub-id pub-id-type="pmid">17931419</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Schaeybroeck</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Chemotherapy-induced epidermal growth factor receptor activation determines response to
combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells</article-title><source>Mol. Cancer Ther</source><volume>5</volume><fpage>1154</fpage><lpage>1165</lpage><year>2006</year><pub-id pub-id-type="pmid">16731747</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism
conferring sensitivity to gefitinib</article-title><source>Syst. Biol. (Stevenage)</source><volume>153</volume><fpage>457</fpage><lpage>466</lpage><year>2006</year><pub-id pub-id-type="pmid">17186707</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>R.P.</given-names></name><name><surname>Petricoin</surname><given-names>E.F.</given-names></name><name><surname>Liotta</surname><given-names>L.A.</given-names></name></person-group><article-title>A mathematical model of combination therapy using the EGFR signaling network</article-title><source>Biosystems</source><volume>80</volume><fpage>57</fpage><lpage>69</lpage><year>2005</year><pub-id pub-id-type="pmid">15740835</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>F.</given-names></name><name><surname>Rateitschak</surname><given-names>K.</given-names></name><name><surname>Kossow</surname><given-names>C.</given-names></name><name><surname>Wolkenhauer</surname><given-names>O.</given-names></name><name><surname>Jaster</surname><given-names>R.</given-names></name></person-group><article-title>Insights into erlotinib action in pancreatic cancer cells using a combined experimental and
mathematical approach</article-title><source>World J. Gastroenterol</source><volume>18</volume><fpage>6226</fpage><lpage>6234</lpage><year>2012</year><pub-id pub-id-type="pmid">23180942</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naruo</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor mutation in combination with expression of MIG6 alters
gefitinib sensitivity</article-title><source>BMC Syst. Biol</source><volume>5</volume><fpage>29</fpage><year>2011</year><pub-id pub-id-type="pmid">21333004</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purvis</surname><given-names>J.</given-names></name><name><surname>Ilango</surname><given-names>V.</given-names></name><name><surname>Radhakrishnan</surname><given-names>R.</given-names></name></person-group><article-title>Role of network branching in eliciting differential short-term signaling responses in the
hypersensitive epidermal growth factor receptor mutants implicated in lung cancer</article-title><source>Biotechnol. Prog</source><volume>24</volume><fpage>540</fpage><lpage>553</lpage><year>2008</year><pub-id pub-id-type="pmid">18412405</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Prusoff</surname><given-names>W.H.</given-names></name></person-group><article-title>Relationship between the inhibition constant (K1) and the concentration of inhibitor which
causes 50 per cent inhibition (I50) of an enzymatic reaction</article-title><source>Biochem. Pharmacol</source><volume>22</volume><fpage>3099</fpage><lpage>3108</lpage><year>1973</year><pub-id pub-id-type="pmid">4202581</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>Z.A.</given-names></name><name><surname>Shokat</surname><given-names>K.M.</given-names></name></person-group><article-title>Features of selective kinase inhibitors</article-title><source>Chem. Biol</source><volume>12</volume><fpage>621</fpage><lpage>637</lpage><year>2005</year><pub-id pub-id-type="pmid">15975507</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ercan</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor</article-title><source>Oncogene</source><volume>29</volume><fpage>2346</fpage><lpage>2356</lpage><year>2010</year><pub-id pub-id-type="pmid">20118985</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor
tyrosine kinase inhibitor gefitinib (&#8216;Iressa', ZD1839) in Japanese patients with solid
malignant tumors</article-title><source>Ann. Oncol</source><volume>14</volume><fpage>922</fpage><lpage>930</lpage><year>2003</year><pub-id pub-id-type="pmid">12796031</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzara</surname><given-names>M.J.</given-names></name><name><surname>Lauffenburger</surname><given-names>D.A.</given-names></name></person-group><article-title>Quantitative modeling perspectives on the ErbB system of cell regulatory processes</article-title><source>Exp. Cell Res</source><volume>315</volume><fpage>717</fpage><lpage>725</lpage><year>2009</year><pub-id pub-id-type="pmid">19022246</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimatsu</surname><given-names>M.</given-names></name><name><surname>Takagi</surname><given-names>H.</given-names></name><name><surname>Ota</surname><given-names>K.G.</given-names></name><name><surname>Iwamoto</surname><given-names>R.</given-names></name><name><surname>Yanagida</surname><given-names>T.</given-names></name><name><surname>Sako</surname><given-names>Y.</given-names></name></person-group><article-title>Multiple-state reactions between the epidermal growth factor receptor and Grb2 as observed
by using single-molecule analysis</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>104</volume><fpage>18013</fpage><lpage>18018</lpage><year>2007</year><pub-id pub-id-type="pmid">17991782</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julien</surname><given-names>S.G.</given-names></name><name><surname>Dub&#233;</surname><given-names>N.</given-names></name><name><surname>Hardy</surname><given-names>S.</given-names></name><name><surname>Tremblay</surname><given-names>M.L.</given-names></name></person-group><article-title>Inside the human cancer tyrosine phosphatome</article-title><source>Nat. Rev. Cancer</source><volume>11</volume><fpage>35</fpage><lpage>49</lpage><year>2011</year><pub-id pub-id-type="pmid">21179176</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>L.G.</given-names></name><etal/></person-group><article-title>Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals
frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>108</volume><fpage>19024</fpage><lpage>19029</lpage><year>2011</year><pub-id pub-id-type="pmid">22065749</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkovich</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and
brain cancers</article-title><source>Cancer Discov</source><volume>2</volume><fpage>450</fpage><lpage>457</lpage><year>2012</year><pub-id pub-id-type="pmid">22588882</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>A.R.</given-names></name><name><surname>Tadaki</surname><given-names>D.K.</given-names></name><name><surname>Niyogi</surname><given-names>S.K.</given-names></name><name><surname>Lauffenburger</surname><given-names>D.A.</given-names></name></person-group><article-title>Intracellular trafficking of epidermal growth factor family ligands is directly influenced
by the pH sensitivity of the receptor/ligand interaction</article-title><source>J. Biol. Chem</source><volume>270</volume><fpage>4334</fpage><lpage>4340</lpage><year>1995</year><pub-id pub-id-type="pmid">7876195</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.K.</given-names></name><name><surname>Tse</surname><given-names>T.T.</given-names></name><name><surname>Sung</surname><given-names>J.J.</given-names></name><name><surname>Li</surname><given-names>Z.J.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Cho</surname><given-names>C.H.</given-names></name></person-group><article-title>Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell
lines</article-title><source>Anticancer Res</source><volume>29</volume><fpage>229</fpage><lpage>234</lpage><year>2009</year><pub-id pub-id-type="pmid">19331154</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ercan</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors</article-title><source>Cancer Discov</source><volume>2</volume><fpage>934</fpage><lpage>947</lpage><year>2012</year><pub-id pub-id-type="pmid">22961667</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance
escaping treatment by the anti-EGFR monoclonal antibody cetuximab</article-title><source>Cancer Res</source><volume>67</volume><fpage>8240</fpage><lpage>8247</lpage><year>2007</year><pub-id pub-id-type="pmid">17804738</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madshus</surname><given-names>I.H.</given-names></name><name><surname>Stang</surname><given-names>E.</given-names></name></person-group><article-title>Internalization and intracellular sorting of the EGF receptor: a model for understanding the
mechanisms of receptor trafficking</article-title><source>J. Cell Sci</source><volume>122</volume><fpage>3433</fpage><lpage>3439</lpage><year>2009</year><pub-id pub-id-type="pmid">19759283</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members</article-title><source>Oncogene</source><volume>27</volume><fpage>3944</fpage><lpage>3956</lpage><year>2008</year><pub-id pub-id-type="pmid">18297114</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monast</surname><given-names>C.S.</given-names></name><name><surname>Furcht</surname><given-names>C.M.</given-names></name><name><surname>Lazzara</surname><given-names>M.J.</given-names></name></person-group><article-title>Computational analysis of the regulation of EGFR by protein tyrosine phosphatases</article-title><source>Biophys. J</source><volume>102</volume><fpage>2012</fpage><lpage>2021</lpage><year>2012</year><pub-id pub-id-type="pmid">22824264</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batzer</surname><given-names>A.G.</given-names></name><name><surname>Rotin</surname><given-names>D.</given-names></name><name><surname>Ure&#241;a</surname><given-names>J.M.</given-names></name><name><surname>Skolnik</surname><given-names>E.Y.</given-names></name><name><surname>Schlessinger</surname><given-names>J.</given-names></name></person-group><article-title>Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor</article-title><source>Mol. Cell. Biol</source><volume>14</volume><fpage>5192</fpage><lpage>5201</lpage><year>1994</year><pub-id pub-id-type="pmid">7518560</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Marusyk</surname><given-names>A.</given-names></name><name><surname>Sorkin</surname><given-names>A.</given-names></name></person-group><article-title>Grb2 regulates internalization of EGF receptors through clathrin-coated pits</article-title><source>Mol. Biol. Cell</source><volume>14</volume><fpage>858</fpage><lpage>870</lpage><year>2003</year><pub-id pub-id-type="pmid">12631709</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gale</surname><given-names>N.W.</given-names></name><name><surname>Kaplan</surname><given-names>S.</given-names></name><name><surname>Lowenstein</surname><given-names>E.J.</given-names></name><name><surname>Schlessinger</surname><given-names>J.</given-names></name><name><surname>Bar-Sagi</surname><given-names>D.</given-names></name></person-group><article-title>Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras</article-title><source>Nature</source><volume>363</volume><fpage>88</fpage><lpage>92</lpage><year>1993</year><pub-id pub-id-type="pmid">8386805</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Cleveland</surname><given-names>T.E.</given-names><suffix>4th</suffix></name><name><surname>Bouyain</surname><given-names>S.</given-names></name><name><surname>Byrne</surname><given-names>P.O.</given-names></name><name><surname>Longo</surname><given-names>P.A.</given-names></name><name><surname>Leahy</surname><given-names>D.J.</given-names></name></person-group><article-title>A single ligand is sufficient to activate EGFR dimers</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>109</volume><fpage>10861</fpage><lpage>10866</lpage><year>2012</year><pub-id pub-id-type="pmid">22699492</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Masui</surname><given-names>H.</given-names></name><name><surname>Altas</surname><given-names>I.</given-names></name><name><surname>Mendelsohn</surname><given-names>J.</given-names></name></person-group><article-title>Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments
of 225 anti-epidermal growth factor receptor monoclonal antibodies</article-title><source>Cancer Res</source><volume>53</volume><fpage>4322</fpage><lpage>4328</lpage><year>1993</year><pub-id pub-id-type="pmid">8364927</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>C.M.</given-names></name><name><surname>Overholser</surname><given-names>K.A.</given-names></name><name><surname>Sorkin</surname><given-names>A.</given-names></name><name><surname>Carpenter</surname><given-names>G.</given-names></name></person-group><article-title>Analysis of the influences of the E5 transforming protein on kinetic parameters of epidermal
growth factor binding and metabolism</article-title><source>J. Cell. Physiol</source><volume>152</volume><fpage>253</fpage><lpage>263</lpage><year>1992</year><pub-id pub-id-type="pmid">1639860</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoyab</surname><given-names>M.</given-names></name><name><surname>Plowman</surname><given-names>G.D.</given-names></name><name><surname>McDonald</surname><given-names>V.L.</given-names></name><name><surname>Bradley</surname><given-names>J.G.</given-names></name><name><surname>Todaro</surname><given-names>G.J.</given-names></name></person-group><article-title>Structure and function of human amphiregulin: a member of the epidermal growth factor
family</article-title><source>Science</source><volume>243</volume><fpage>1074</fpage><lpage>1076</lpage><year>1989</year><pub-id pub-id-type="pmid">2466334</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Modulation of the receptor binding affinity of amphiregulin by modification of its carboxyl
terminal tail</article-title><source>Biochim. Biophys. Acta</source><volume>1266</volume><fpage>83</fpage><lpage>90</lpage><year>1995</year><pub-id pub-id-type="pmid">7718625</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>K.A.</given-names></name><name><surname>Place</surname><given-names>T.L.</given-names></name><name><surname>Lill</surname><given-names>N.L.</given-names></name></person-group><article-title>EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor
fate</article-title><source>Biochem. J</source><volume>410</volume><fpage>585</fpage><lpage>594</lpage><year>2008</year><pub-id pub-id-type="pmid">18045238</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roepstorff</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Differential effects of EGFR ligands on endocytic sorting of the receptor</article-title><source>Traffic</source><volume>10</volume><fpage>1115</fpage><lpage>1127</lpage><year>2009</year><pub-id pub-id-type="pmid">19531065</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal
growth factor receptor vIII on the cell surface</article-title><source>Anticancer Res</source><volume>27</volume><fpage>3355</fpage><lpage>3366</lpage><year>2007</year><pub-id pub-id-type="pmid">17970081</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albanell</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin
from cancer patients: histopathologic and molecular consequences of receptor inhibition</article-title><source>J. Clin. Oncol</source><volume>20</volume><fpage>110</fpage><lpage>124</lpage><year>2002</year><pub-id pub-id-type="pmid">11773160</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukohara</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing
epidermal growth factor receptor mutations</article-title><source>J. Natl. Cancer Inst</source><volume>97</volume><fpage>1185</fpage><lpage>1194</lpage><year>2005</year><pub-id pub-id-type="pmid">16106023</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>M.W.</given-names></name><name><surname>Pedersen</surname><given-names>N.</given-names></name><name><surname>Ottesen</surname><given-names>L.H.</given-names></name><name><surname>Poulsen</surname><given-names>H.S.</given-names></name></person-group><article-title>Differential response to gefitinib of cells expressing normal EGFR and the mutant
EGFRvIII</article-title><source>Br. J. Cancer</source><volume>93</volume><fpage>915</fpage><lpage>923</lpage><year>2005</year><pub-id pub-id-type="pmid">16189524</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berkers</surname><given-names>J.A.</given-names></name><name><surname>van Bergen en Henegouwen</surname><given-names>P.M.</given-names></name><name><surname>Boonstra</surname><given-names>J.</given-names></name></person-group><article-title>Three classes of epidermal growth factor receptors on HeLa cells</article-title><source>J. Biol. Chem</source><volume>266</volume><fpage>922</fpage><lpage>927</lpage><year>1991</year><pub-id pub-id-type="pmid">1985972</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kholodenko</surname><given-names>B.N.</given-names></name><name><surname>Demin</surname><given-names>O.V.</given-names></name><name><surname>Moehren</surname><given-names>G.</given-names></name><name><surname>Hoek</surname><given-names>J.B.</given-names></name></person-group><article-title>Quantification of short term signaling by the epidermal growth factor receptor</article-title><source>J. Biol. Chem</source><volume>274</volume><fpage>30169</fpage><lpage>30181</lpage><year>1999</year><pub-id pub-id-type="pmid">10514507</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamaraeva</surname><given-names>M.V.</given-names></name><name><surname>Sabirov</surname><given-names>R.Z.</given-names></name><name><surname>Maeno</surname><given-names>E.</given-names></name><name><surname>Ando-Akatsuka</surname><given-names>Y.</given-names></name><name><surname>Bessonova</surname><given-names>S.V.</given-names></name><name><surname>Okada</surname><given-names>Y.</given-names></name></person-group><article-title>Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with
intracellular luciferase</article-title><source>Cell Death Differ</source><volume>12</volume><fpage>1390</fpage><lpage>1397</lpage><year>2005</year><pub-id pub-id-type="pmid">15905877</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzara</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to
gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating
mutations</article-title><source>Cancer Res</source><volume>70</volume><fpage>3843</fpage><lpage>3850</lpage><year>2010</year><pub-id pub-id-type="pmid">20406974</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>A.C.</given-names></name><name><surname>Kovach</surname><given-names>J.S.</given-names></name><name><surname>Vuk-Pavlovi&#263;</surname><given-names>S.</given-names></name></person-group><article-title>Binding, internalization, and intracellular processing of protein ligands. Derivation of
rate constants by computer modeling</article-title><source>J. Biol. Chem</source><volume>262</volume><fpage>6494</fpage><lpage>6499</lpage><year>1987</year><pub-id pub-id-type="pmid">2952651</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor
dimerization</article-title><source>Cell</source><volume>149</volume><fpage>860</fpage><lpage>870</lpage><year>2012</year><pub-id pub-id-type="pmid">22579287</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>B.S.</given-names></name><name><surname>Opresko</surname><given-names>L.K.</given-names></name><name><surname>Wiley</surname><given-names>H.S.</given-names></name><name><surname>Lauffenburger</surname><given-names>D.</given-names></name></person-group><article-title>Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor
endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels</article-title><source>J. Biol. Chem</source><volume>278</volume><fpage>23343</fpage><lpage>23351</lpage><year>2003</year><pub-id pub-id-type="pmid">12686539</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y.X.</given-names></name><name><surname>Wong</surname><given-names>L.</given-names></name><name><surname>Deb</surname><given-names>T.B.</given-names></name><name><surname>Johnson</surname><given-names>G.R.</given-names></name></person-group><article-title>Ligand regulates epidermal growth factor receptor kinase specificity: activation increases
preference for GAB1 and SHC versus autophosphorylation sites</article-title><source>J. Biol. Chem</source><volume>279</volume><fpage>38143</fpage><lpage>38150</lpage><year>2004</year><pub-id pub-id-type="pmid">15231819</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>B.S.</given-names></name><name><surname>Opresko</surname><given-names>L.K.</given-names></name><name><surname>Wiley</surname><given-names>H.S.</given-names></name><name><surname>Lauffenburger</surname><given-names>D.</given-names></name></person-group><article-title>Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2
(HER2) levels and locations: quantitative analysis of HER2 overexpression effects</article-title><source>Cancer Res</source><volume>63</volume><fpage>1130</fpage><lpage>1137</lpage><year>2003</year><pub-id pub-id-type="pmid">12615732</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Figure S1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439x1.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob2"><label>Supplementary Figure S2</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439x2.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob3"><label>Supplementary Figure S3</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439x3.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob4"><label>Supplementary Materials S4</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439x4.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p><bold>Model topology of processes leading to epidermal growth factor receptor (EGFR) phosphorylation
and therapeutic inhibition of this process.</bold> (<bold>a</bold>) Ligand (<italic>L</italic>) and cetuximab
(<italic>C</italic>) compete for binding to the EGFR extracellular domain while ATP (<italic>A</italic>) and
gefitinib (<italic>G</italic>) compete for binding to the EGFR kinase domain (<italic>K</italic>). Ligand binding
promotes EGFR dimerization and ATP-dependent phosphorylation (<italic>P</italic>) of cytoplasmic tyrosines
(<italic>Y</italic>), enabling receptor binding to intracellular adaptor proteins (e.g., GRB2). EGFR-GRB2
binding permits EGFR internalization. (<bold>b</bold>) Gefitinib and cetuximab mediate reductions in the
phosphorylation of dimerized and phosphorylated EGFR through different mechanisms. ATP dissociation
from EGFR allows gefitinib to bind, prolonging the time the receptor remains dephosphorylated after
being acted upon by protein tyrosine phosphatases (PTP). Cetuximab can bind phosphorylated receptors
once they uncouple from dimers and ligands dissociate, which slows further rounds of ligand binding
and dimerization and prolongs the time the receptor remains dephosphorylated after being acted upon
by PTPs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p><bold>Predicted therapeutic <italic>IC</italic></bold><sub><bold>50</bold></sub>
<bold>values</bold>. (<bold>a</bold>) For a range of gefitinib or cetuximab concentrations and 1.6 nmol/l EGF or
amphiregulin (AR), the amount of steady-state phosphorylated epidermal growth factor receptor (EGFR)
(pEGFR) was computed and normalized to the amount of pEGFR in the absence of therapeutic. (<bold>b</bold>)
From the data shown in panel (<bold>a</bold>), gefitinib and cetuximab <italic>IC</italic><sub>50</sub> values
were calculated for each ligand/therapeutic pair. (<bold>c</bold> and <bold>d</bold>) Calculations in panels
(<bold>a</bold>) and (<bold>b</bold>) were repeated for 160 nmol/l AR and compared to results for 1.6 nmol/l
EGF.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439f2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p><bold>Effects of the rates of cycling of ligand or therapeutic binding and unbinding</bold>. Gefitinib
and cetuximab <italic>IC</italic><sub>50</sub> values were calculated for the indicated fold-changes in
ligand or drug cycling factor, a constant by which the ligand or drug association and dissociation
rate constants are multiplied such that binding/unbinding rates change without altering affinities.
Ligand cycling rates corresponding to 1.6 nmol/l epidermal growth factor (EGF) and 160 nmol/l
amphiregulin (AR) are indicated by the yellow and white dots, respectively. 160 nmol/l AR is
equivalent to 1.6 nmol/l EGF with a ligand cycling factor of 100 because AR is treated as
dissociating from EGFR 100 times faster than EGF and the 100-fold greater AR concentration leads to
a 100-fold increase in AR's association relative to EGF. The analysis was performed for
(<bold>a</bold>) gefitinib and (<bold>b</bold>) cetuximab with the base model parameters. (<bold>c</bold> and
<bold>d</bold>) The simulations in panels (<bold>a</bold>) and (<bold>b</bold>) were repeated but with (<bold>c</bold>) the
rate constants for phosphorylation within ligand-bound dimers (<italic>k</italic><sub><italic>p,L</italic></sub>)
and dephosphorylation at the cell surface and in the cell interior
(<italic>k</italic><sub><italic>dp,s</italic></sub> and <italic>k</italic><sub><italic>dp,i</italic></sub>, respectively) reduced by
100-fold and (<bold>d</bold>) the rate constants for receptor dimerization at the cell surface and in the
cell interior (<italic>k</italic><sub><italic>d,fs</italic></sub> and <italic>k</italic><sub><italic>d,fi</italic></sub>,
respectively) and uncoupling of ligand-bound receptor dimers (<italic>k</italic><sub><italic>d,rL</italic></sub>)
reduced by 10<sup>3</sup>-fold, respectively. For panels (<bold>a&#8211;d</bold>), the grey scale
colorbars at left show the percent of phosphorylated EGFR (pEGFR) in the absence of drug as a
function of ligand cycling factor. The log<sub>10</sub>(<italic>IC</italic><sub>50</sub>), with
<italic>IC</italic><sub>50</sub> in &#181;mol/l units, as a function of ligand and drug cycling factors is
shown in colored contour plots, with the color scale shown at right of each contour.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439f3"/></fig><fig id="fig4"><label>Figure 4</label><caption><p><bold>Local sensitivity analysis to identify determinants of <italic>IC</italic></bold><sub><bold>50</bold></sub>
<bold>for gefitinib and cetuximab</bold>. (<bold>a</bold> and <bold>b</bold>) Sensitivity of <italic>IC</italic><sub>50</sub>
values to perturbations of 10-fold in each of the model parameters was computed for (<bold>a</bold>)
gefitinib or (<bold>b</bold>) cetuximab. Sensitivities were reported as the absolute value of the
difference in the logarithm of the base <italic>IC</italic><sub>50</sub> and the perturbed
<italic>IC</italic><sub>50</sub> values and then normalized to the maximum. This analysis was performed for
1.6 nmol/l epidermal growth factor (EGF), 1.6 nmol/l amphiregulin (AR), and 160 nmol/l AR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439f4"/></fig><fig id="fig5"><label>Figure 5</label><caption><p><bold>Prediction of and local sensitivity analyses for the time scale with which gefitinib and
cetuximab drive epidermal growth factor receptor (EGFR) dephosphorylation</bold>. The model was used to
predict the percent of phosphorylated EGFR (% pEGFR) observed in response to a 5&#8201;min
treatment with (<bold>a</bold> and <bold>b</bold>) 1.6 nmol/l EGF, (<bold>c</bold>) 1.6 nmol/l amphiregulin (AR), or
(<bold>d</bold>) 160 nmol/l AR, followed by a chase with 1 &#956;mol/l gefitinib or cetuximab. For
(<bold>b</bold>), the internalization rate constant (<italic>k</italic><sub><italic>i</italic></sub>) was set to zero at
<italic>t</italic> = 0&#8201;min for all conditions and the rate constants for ligand-receptor association
and dissociation (<italic>k</italic><sub><italic>L,f</italic></sub> and <italic>k</italic><sub><italic>L,r</italic></sub>,
respectively) were increased by 100-fold for the cetuximab condition at <italic>t</italic> = 5&#8201;min.
(<bold>e</bold> and <bold>f</bold>) Sensitivity of <italic>t</italic><sub>50</sub> values to perturbations of 10-fold in
each of the model parameters was computed for (<bold>e</bold>) gefitinib or (<bold>f</bold>) cetuximab.
Sensitivities were reported as the absolute value of the difference in the logarithm of the base
<italic>t</italic><sub>50</sub> and the perturbed <italic>t</italic><sub>50</sub> and then normalized to the
maximum. Sensitivity analyses were performed for 1.6 nmol/l EGF, 1.6 nmol/l AR, and 160 nmol/l AR
and 1 &#956;mol/l therapeutic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439f5"/></fig><fig id="fig6"><label>Figure 6</label><caption><p><bold>Effects of gefitinib and cetuximab cotreatment</bold>. (<bold>a&#8211;c</bold>) The model was used to
predict the steady-state percent of phosphorylated epidermal growth factor receptor (pEGFR) as a
function of cetuximab and gefitinib concentrations for (<bold>a</bold>) 1.6 nmol/l EGF, (<bold>b</bold>) 1.6
nmol/l amphiregulin (AR), or (<bold>c</bold>) 160 nmol/l AR. (<bold>d&#8211;f</bold>) Synergy, defined as the
reduction in receptor phosphorylation resulting from cotreatment minus the reductions in receptor
phosphorylation following treatment with each therapeutic alone, was calculated as a function of
cetuximab and gefitinib concentrations for the same ligand concentrations as in (<bold>a&#8211;c</bold>).
(<bold>g&#8211;i</bold>) To estimate therapeutic efficiency, pEGFR (<bold>a&#8211;c</bold>), synergy
(<bold>d&#8211;f</bold>), and the logarithm of the sum of the drug concentrations were scaled to each
range between 0 and 1 and then summed for all drug combinations. Based on this definition,
therapeutic efficiency is highest for low pEGFR, high synergy, and low amount of drug.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439f6"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Model parameters</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psp201439t1"/></table-wrap></floats-group></article>